Tag Archives: possible
#435614 3 Easy Ways to Evaluate AI Claims
When every other tech startup claims to use artificial intelligence, it can be tough to figure out if an AI service or product works as advertised. In the midst of the AI “gold rush,” how can you separate the nuggets from the fool’s gold?
There’s no shortage of cautionary tales involving overhyped AI claims. And applying AI technologies to health care, education, and law enforcement mean that getting it wrong can have real consequences for society—not just for investors who bet on the wrong unicorn.
So IEEE Spectrum asked experts to share their tips for how to identify AI hype in press releases, news articles, research papers, and IPO filings.
“It can be tricky, because I think the people who are out there selling the AI hype—selling this AI snake oil—are getting more sophisticated over time,” says Tim Hwang, director of the Harvard-MIT Ethics and Governance of AI Initiative.
The term “AI” is perhaps most frequently used to describe machine learning algorithms (and deep learning algorithms, which require even less human guidance) that analyze huge amounts of data and make predictions based on patterns that humans might miss. These popular forms of AI are mostly suited to specialized tasks, such as automatically recognizing certain objects within photos. For that reason, they are sometimes described as “weak” or “narrow” AI.
Some researchers and thought leaders like to talk about the idea of “artificial general intelligence” or “strong AI” that has human-level capacity and flexibility to handle many diverse intellectual tasks. But for now, this type of AI remains firmly in the realm of science fiction and is far from being realized in the real world.
“AI has no well-defined meaning and many so-called AI companies are simply trying to take advantage of the buzz around that term,” says Arvind Narayanan, a computer scientist at Princeton University. “Companies have even been caught claiming to use AI when, in fact, the task is done by human workers.”
Here are three ways to recognize AI hype.
Look for Buzzwords
One red flag is what Hwang calls the “hype salad.” This means stringing together the term “AI” with many other tech buzzwords such as “blockchain” or “Internet of Things.” That doesn’t automatically disqualify the technology, but spotting a high volume of buzzwords in a post, pitch, or presentation should raise questions about what exactly the company or individual has developed.
Other experts agree that strings of buzzwords can be a red flag. That’s especially true if the buzzwords are never really explained in technical detail, and are simply tossed around as vague, poorly-defined terms, says Marzyeh Ghassemi, a computer scientist and biomedical engineer at the University of Toronto in Canada.
“I think that if it looks like a Google search—picture ‘interpretable blockchain AI deep learning medicine’—it's probably not high-quality work,” Ghassemi says.
Hwang also suggests mentally replacing all mentions of “AI” in an article with the term “magical fairy dust.” It’s a way of seeing whether an individual or organization is treating the technology like magic. If so—that’s another good reason to ask more questions about what exactly the AI technology involves.
And even the visual imagery used to illustrate AI claims can indicate that an individual or organization is overselling the technology.
“I think that a lot of the people who work on machine learning on a day-to-day basis are pretty humble about the technology, because they’re largely confronted with how frequently it just breaks and doesn't work,” Hwang says. “And so I think that if you see a company or someone representing AI as a Terminator head, or a big glowing HAL eye or something like that, I think it’s also worth asking some questions.”
Interrogate the Data
It can be hard to evaluate AI claims without any relevant expertise, says Ghassemi at the University of Toronto. Even experts need to know the technical details of the AI algorithm in question and have some access to the training data that shaped the AI model’s predictions. Still, savvy readers with some basic knowledge of applied statistics can search for red flags.
To start, readers can look for possible bias in training data based on small sample sizes or a skewed population that fails to reflect the broader population, Ghassemi says. After all, an AI model trained only on health data from white men would not necessarily achieve similar results for other populations of patients.
“For me, a red flag is not demonstrating deep knowledge of how your labels are defined.”
—Marzyeh Ghassemi, University of Toronto
How machine learning and deep learning models perform also depends on how well humans labeled the sample datasets use to train these programs. This task can be straightforward when labeling photos of cats versus dogs, but gets more complicated when assigning disease diagnoses to certain patient cases.
Medical experts frequently disagree with each other on diagnoses—which is why many patients seek a second opinion. Not surprisingly, this ambiguity can also affect the diagnostic labels that experts assign in training datasets. “For me, a red flag is not demonstrating deep knowledge of how your labels are defined,” Ghassemi says.
Such training data can also reflect the cultural stereotypes and biases of the humans who labeled the data, says Narayanan at Princeton University. Like Ghassemi, he recommends taking a hard look at exactly what the AI has learned: “A good way to start critically evaluating AI claims is by asking questions about the training data.”
Another red flag is presenting an AI system’s performance through a single accuracy figure without much explanation, Narayanan says. Claiming that an AI model achieves “99 percent” accuracy doesn’t mean much without knowing the baseline for comparison—such as whether other systems have already achieved 99 percent accuracy—or how well that accuracy holds up in situations beyond the training dataset.
Narayanan also emphasized the need to ask questions about an AI model’s false positive rate—the rate of making wrong predictions about the presence of a given condition. Even if the false positive rate of a hypothetical AI service is just one percent, that could have major consequences if that service ends up screening millions of people for cancer.
Readers can also consider whether using AI in a given situation offers any meaningful improvement compared to traditional statistical methods, says Clayton Aldern, a data scientist and journalist who serves as managing director for Caldern LLC. He gave the hypothetical example of a “super-duper-fancy deep learning model” that achieves a prediction accuracy of 89 percent, compared to a “little polynomial regression model” that achieves 86 percent on the same dataset.
“We're talking about a three-percentage-point increase on something that you learned about in Algebra 1,” Aldern says. “So is it worth the hype?”
Don’t Ignore the Drawbacks
The hype surrounding AI isn’t just about the technical merits of services and products driven by machine learning. Overblown claims about the beneficial impacts of AI technology—or vague promises to address ethical issues related to deploying it—should also raise red flags.
“If a company promises to use its tech ethically, it is important to question if its business model aligns with that promise,” Narayanan says. “Even if employees have noble intentions, it is unrealistic to expect the company as a whole to resist financial imperatives.”
One example might be a company with a business model that depends on leveraging customers’ personal data. Such companies “tend to make empty promises when it comes to privacy,” Narayanan says. And, if companies hire workers to produce training data, it’s also worth asking whether the companies treat those workers ethically.
The transparency—or lack thereof—about any AI claim can also be telling. A company or research group can minimize concerns by publishing technical claims in peer-reviewed journals or allowing credible third parties to evaluate their AI without giving away big intellectual property secrets, Narayanan says. Excessive secrecy is a big red flag.
With these strategies, you don’t need to be a computer engineer or data scientist to start thinking critically about AI claims. And, Narayanan says, the world needs many people from different backgrounds for societies to fully consider the real-world implications of AI.
Editor’s Note: The original version of this story misspelled Clayton Aldern’s last name as Alderton. Continue reading
#435605 All of the Winners in the DARPA ...
The first competitive event in the DARPA Subterranean Challenge concluded last week—hopefully you were able to follow along on the livestream, on Twitter, or with some of the articles that we’ve posted about the event. We’ll have plenty more to say about how things went for the SubT teams, but while they take a bit of a (well earned) rest, we can take a look at the winning teams as well as who won DARPA’s special superlative awards for the competition.
First Place: Team Explorer (25/40 artifacts found)
With their rugged, reliable robots featuring giant wheels and the ability to drop communications nodes, Team Explorer was in the lead from day 1, scoring in double digits on every single run.
Second Place: Team CoSTAR (11/40 artifacts found)
Team CoSTAR had one of the more diverse lineups of robots, and they switched up which robots they decided to send into the mine as they learned more about the course.
Third Place: Team CTU-CRAS (10/40 artifacts found)
While many teams came to SubT with DARPA funding, Team CTU-CRAS was self-funded, making them eligible for a special $200,000 Tunnel Circuit prize.
DARPA also awarded a bunch of “superlative awards” after SubT:
Most Accurate Artifact: Team Explorer
To score a point, teams had to submit the location of an artifact that was correct to within 5 meters of the artifact itself. However, DARPA was tracking the artifact locations with much higher precision—for example, the “zero” point on the backpack artifact was the center of the label on the front, which DARPA tracked to the millimeter. Team Explorer managed to return the location of a backpack with an error of just 0.18 meter, which is kind of amazing.
Down to the Wire: Team CSIRO Data61
With just an hour to find as many artifacts as possible, teams had to find the right balance between sending robots off to explore and bringing them back into communication range to download artifact locations. Team CSIRO Data61 cut their last point pretty close, sliding their final point in with a mere 22 seconds to spare.
Most Distinctive Robots: Team Robotika
Team Robotika had some of the quirkiest and most recognizable robots, which DARPA recognized with the “Most Distinctive” award. Robotika told us that part of the reason for that distinctiveness was practical—having a robot that was effectively in two parts meant that they could disassemble it so that it would fit in the baggage compartment of an airplane, very important for a team based in the Czech Republic.
Most Robots Per Person: Team Coordinated Robotics
Kevin Knoedler, who won NASA’s Space Robotics Challenge entirely by himself, brought his own personal swarm of drones to SubT. With a ratio of seven robots to one human, Kevin was almost certainly the hardest working single human at the challenge.
Fan Favorite: Team NCTU
Photo: Evan Ackerman/IEEE Spectrum
The Fan Favorite award went to the team that was most popular on Twitter (with the #SubTChallenge hashtag), and it may or may not be the case that I personally tweeted enough about Team NCTU’s blimp to win them this award. It’s also true that whenever we asked anyone on other teams what their favorite robot was (besides their own, of course), the blimp was overwhelmingly popular. So either way, the award is well deserved.
DARPA shared this little behind-the-scenes clip of the blimp in action (sort of), showing what happened to the poor thing when the mine ventilation system was turned on between runs and DARPA staff had to chase it down and rescue it:
The thing to keep in mind about the results of the Tunnel Circuit is that unlike past DARPA robotics challenges (like the DRC), they don’t necessarily indicate how things are going to go for the Urban or Cave circuits because of how different things are going to be. Explorer did a great job with a team of rugged wheeled vehicles, which turned out to be ideal for navigating through mines, but they’re likely going to need to change things up substantially for the rest of the challenges, where the terrain will be much more complex.
DARPA hasn’t provided any details on the location of the Urban Circuit yet; all we know is that it’ll be sometime in February 2020. This gives teams just six months to take all the lessons that they learned from the Tunnel Circuit and update their hardware, software, and strategies. What were those lessons, and what do teams plan to do differently next year? Check back next week, and we’ll tell you.
[ DARPA SubT ] Continue reading
#435575 How an AI Startup Designed a Drug ...
Discovering a new drug can take decades, billions of dollars, and untold man hours from some of the smartest people on the planet. Now a startup says it’s taken a significant step towards speeding the process up using AI.
The typical drug discovery process involves carrying out physical tests on enormous libraries of molecules, and even with the help of robotics it’s an arduous process. The idea of sidestepping this by using computers to virtually screen for promising candidates has been around for decades. But progress has been underwhelming, and it’s still not a major part of commercial pipelines.
Recent advances in deep learning, however, have reignited hopes for the field, and major pharma companies have started tying up with AI-powered drug discovery startups. And now Insilico Medicine has used AI to design a molecule that effectively targets a protein involved in fibrosis—the formation of excess fibrous tissue—in mice in just 46 days.
The platform the company has developed combines two of the hottest sub-fields of AI: the generative adversarial networks, or GANs, which power deepfakes, and reinforcement learning, which is at the heart of the most impressive game-playing AI advances of recent years.
In a paper in Nature Biotechnology, the company’s researchers describe how they trained their model on all the molecules already known to target this protein as well as many other active molecules from various datasets. The model was then used to generate 30,000 candidate molecules.
Unlike most previous efforts, they went a step further and selected the most promising molecules for testing in the lab. The 30,000 candidates were whittled down to just 6 using more conventional drug discovery approaches and were then synthesized in the lab. They were put through increasingly stringent tests, but the leading candidate was found to be effective at targeting the desired protein and behaved as one would hope a drug would.
The authors are clear that the results are just a proof-of-concept, which company CEO Alex Zhavoronkov told Wired stemmed from a challenge set by a pharma partner to design a drug as quickly as possible. But they say they were able to carry out the process faster than traditional methods for a fraction of the cost.
There are some caveats. For a start, the protein being targeted is already very well known and multiple effective drugs exist for it. That gave the company a wealth of data to train their model on, something that isn’t the case for many of the diseases where we urgently need new drugs.
The company’s platform also only targets the very initial stages of the drug discovery process. The authors concede in their paper that the molecules would still take considerable optimization in the lab before they’d be true contenders for clinical trials.
“And that is where you will start to begin to commence to spend the vast piles of money that you will eventually go through in trying to get a drug to market,” writes Derek Lowe in his blog In The Pipeline. The part of the discovery process that the platform tackles represents a tiny fraction of the total cost of drug development, he says.
Nonetheless, the research is a definite advance for virtual screening technology and an important marker of the potential of AI for designing new medicines. Zhavoronkov also told Wired that this research was done more than a year ago, and they’ve since adapted the platform to go after harder drug targets with less data.
And with big pharma companies desperate to slash their ballooning development costs and find treatments for a host of intractable diseases, they can use all the help they can get.
Image Credit: freestocks.org / Unsplash Continue reading